Evidence map›Paper›PMID 20026874›Full record

ArticleThe Journal of biological chemistry2010

The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1.

Ruth Schietke, Christina Warnecke, Ingrid Wacker, Johannes Schödel, David R Mole, Valentina Campean, Kerstin Amann, Margarete Goppelt-Struebe, Jürgen Behrens, Kai-Uwe Eckardt and 1 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 143 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
143citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

143 citing papers in PubMed, 2 syntheses or guidelines pooled it, 248 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. LOXL2 inhibition ameliorates pulmonary artery remodeling in pulmonary hypertension.American journal of physiology. Lung cellular and molecular physiology · 2024
    Article
  15. Article
  16. Revisiting reactive oxygen species production in hypoxia.Pflugers Archiv : European journal of physiology · 2024
    Review
  17. Review
  18. Article
  19. Article
  20. Article

83 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Ruth SchietkeInterdisciplinary Centre for Clinical Research, University of Erlangen-Nuremberg, 91054 Erlangen, Germany.
Christina Warnecke
Ingrid Wacker
Johannes Schödel
David R Mole
Valentina Campean
Kerstin Amann
Margarete Goppelt-Struebe
Jürgen Behrens
Kai-Uwe Eckardt
Michael S Wiesener
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversity of Oxford · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Hypoxia has been shown to promote tumor metastasis and lead to therapy resistance. Recent work has demonstrated that hypoxia represses E-cadherin expression, a hallmark of epithelial to mesenchymal transition, which is believed to amplify tumor aggressiveness. The molecular mechanism of E-cadherin repression is unknown, yet lysyl oxidases have been implicated to be involved. Gene expression of lysyl oxidase (LOX) and the related LOX-like 2 (LOXL2) is strongly induced by hypoxia. In addition to the previously demonstrated LOX, we characterize LOXL2 as a direct transcriptional target of HIF-1. We demonstrate that activation of lysyl oxidases is required and sufficient for hypoxic repression of E-cadherin, which mediates cellular transformation and takes effect in cellular invasion assays. Our data support a molecular pathway from hypoxia to cellular transformation. It includes up-regulation of HIF and subsequent transcriptional induction of LOX and LOXL2, which repress E-cadherin and induce epithelial to mesenchymal transition. Lysyl oxidases could be an attractive molecular target for cancers of epithelial origin, in particular because they are partly extracellular.

Indexed as

Cell Transformation, NeoplasticAmino Acid OxidoreductasesCadherinsCell LineEpithelial CellsGene Expression Regulation, EnzymologicHumansHypoxiaHypoxia-Inducible Factor 1, alpha SubunitMesodermNeoplasm MetastasisProtein-Lysine 6-OxidaseRNA, MessengerUp-RegulationAmino Acid OxidoreductasesCadherinsHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitLOXL2 protein, humanProtein-Lysine 6-OxidaseRNA, Messenger

Identifiers

PMID20026874
PMCPMC2825461
OpenAlexW2161031052

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.